Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
AstraZeneca UMC Utrecht |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00318084 |
The purpose of this study is to determine the diagnostic value of two week treatment with Nexium as a confirmatory test for patients with suspected reflux disease.
Condition | Intervention | Phase |
---|---|---|
GERD |
Drug: Esomeprazole Procedure: Ambulatory 24-hour esophageal pH-monitoring |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | The Proton Pump Inhibitor Test in Reflux Disease: a Study Using Nexium in General Practice Patients |
Estimated Enrollment: | 100 |
Study Start Date: | January 2003 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 25N54 |
Study First Received: | April 25, 2006 |
Last Updated: | August 15, 2007 |
ClinicalTrials.gov Identifier: | NCT00318084 |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Gastroesophageal reflux disease Heartburn Acid-related diseases Acid reflux disease Nexium |
Pyrosis Heartburn Omeprazole Gastroesophageal Reflux |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Ulcer Agents |
Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |